联合早孕期筛查后产前诊断检测与非典型染色体异常:对非侵入性产前检测条件模型的启示
基于澳大利亚维多利亚州全州数据的回顾性队列研究,分析联合早孕期筛查(CFTS)后侵入性产前诊断 uptake 随21三体(T21)风险的变化,以及非典型染色体异常的患病率与检出方法,并比较2014-2015队列与2002-2004历史队列。
要点
- 2014-2015年CFTS队列非典型染色体异常总患病率为0.10%。
- CFTS T21风险>1/10者非典型异常率4.6%,PAPP-A<0.2 MoM者6.9%。
- 55%非典型异常发生于CFTS T21风险<1/300者,最常见经超声检出(47.1%)。
核心结论
- 若对CFTS T21风险>1/100、血清PAPP-A或β-hCG<0.2 MoM、或超声发现异常者提供侵入性产前诊断,可减轻对非侵入性产前检测在高风险后应用时漏诊非典型染色体异常的担忧。
- 该结果对筛查的条件模型有启示。
研究设计与样本
- 回顾性队列研究,使用澳大利亚维多利亚州全州产前数据集。
- 分析分三步:连接血清筛查与诊断结果记录;比较2014-2015队列与2002-2004历史队列按CFTS T21风险类别的诊断检测率;按CFTS T21风险、单个血清分析物水平及其他侵入性诊断指征详细分析2014-2015组非典型异常。
主要发现
- 2014-2015年共发出100 418例CFTS结果,对应146 776例出生(68.4%)。
- 整个CFTS队列非典型染色体异常总患病率为0.10%,在CFTS T21风险>1/10者中最高(4.6%),在血清分析物<0.2 MoM者中PAPP-A为6.9%、β-hCG为5.2%。
- PAPP-A<0.2 MoM的妇女中近一半(49.2%)CFTS T21风险低于1/100。
- 多数(55%)非典型异常发生于CFTS T21风险低于1/300的妇女,最常经超声检查检出(47.1%)。
关键数值与推荐
- 对CFTS T21风险>1/100、血清PAPP-A或β-hCG<0.2 MoM、或超声检出异常者提供侵入性产前诊断(原文结论)。
- 非典型染色体异常总患病率0.10%(整个CFTS队列)。
- CFTS T21风险>1/10者非典型异常率4.6%;PAPP-A<0.2 MoM者6.9%;β-hCG<0.2 MoM者5.2%。
- PAPP-A<0.2 MoM者中49.2% CFTS T21风险<1/100;55%非典型异常发生于CFTS T21风险<1/300者;47.1%经超声检出。
临床怎么用
- 作者结论认为,对CFTS T21风险>1/100、血清PAPP-A或β-hCG<0.2 MoM、或超声检出异常者提供侵入性产前诊断,可减轻对非侵入性产前检测在高风险后应用时漏诊非典型染色体异常的担忧。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate by means of a population-based analysis of a cohort of women who underwent combined first-trimester screening (CFTS), changes in uptake of invasive prenatal diagnosis according to risk of trisomy 21 (T21) on CFTS, and prevalence and methods for ascertainment of atypical chromosome abnormalities. METHODS: This was a retrospective cohort study using state-wide prenatal datasets from Victoria, Australia. A three-step approach was taken to analyze the data: (1) linkage of records between serum screening and diagnostic results; (2) comparison of rates of diagnostic testing according to CFTS T21 risk result category in a 2014-2015 cohort with those of a historical 2002-2004 cohort; (3) detailed analysis of atypical abnormalities in the 2014-2015 group according to CFTS T21 risk result, individual serum analyte level and other indications for invasive diagnostic testing. RESULTS: In 2014-2015, there were 100 418 CFTS results issued for 146 776 births (68.4%). The overall prevalence of atypical chromosome abnormalities in the entire CFTS cohort was 0.10% and was highest in those with CFTS T21 risk > 1 in 10 (4.6%), or serum analyte levels < 0.2 multiples of the median (MoM) (6.9% for pregnancy-associated plasma protein-A (PAPP-A) and 5.2% for beta-human chorionic gonadotropin (β-hCG)). Almost half (49.2%) of women with PAPP-A < 0.2 MoM had a risk for T21 on CFTS of less than 1 in 100. The majority (55%) of atypical abnormalities occurred in women with CFTS T21 risk below 1 in 300, and were most commonly detected on ultrasound examination (47.1%). CONCLUSION: Concerns regarding missed diagnoses of atypical chromosome abnormalities when non-invasive prenatal testing is offered after a result of high risk on CFTS can be mitigated if invasive diagnostic testing is offered to those women with CFTS T21 risk of > 1 in 100, serum PAPP-A or β-hCG < 0.2 MoM, or ultrasound-detected abnormality. This has implications for contingent models of screening. Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd.
引用
- Lindquist A, Poulton A, Halliday J, et al. Prenatal diagnostic testing and atypical chromosome abnormalities following combined first-trimester screening: implications for contingent models of non-invasive prenatal testing. Ultrasound Obstet Gynecol. 2018. PMID: 29226487. doi:10.1002/uog.18979
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。